By proceeding, you agree to our Terms of Use and Privacy Policy.
Board certified medical oncologist with primary expertise in the translational and clinical development of immunotherapies, inclusive of PD-L1 inhibitors, therapeutic cancer vaccines, immune suppressor modulator (anti-IL-8), IDO inhibitor, adoptive N
Talks About #clinicalstrategy #medicalaffairs
Preferred Locations #NorthAmerica
There aren’t many targets like BCMA - well validated, preferentially expressed by mature B lymphocytes and specific to multiple myeloma – meaning that novel drugs against BCMA continue to emerge.
